尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標記)
FITC-Linked Polyclonal Antibody to Plasminogen Activator, Urokinase Receptor (uPAR)
CD87; PLAUR; PLAU-R; U-PAR; URKR; Monocyte Activation Antigen Mo3
- 編號LAA141Mu81
- 物種Mus musculus (Mouse，小鼠)相同的名稱，不同的物種。
- 來源抗體標記
- Ig類型IgG
- 純化方式抗原特異性親和純化
- 標記物熒光素
- 原抗體-
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度500μg/mL
- 且適物種Rattus norvegicus (Rat，大鼠)
- 應用WB; IHC; ICC; IF.
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載英文說明書 中文說明書
- 規(guī)格20μl100μl200μl1ml10ml
- 價格¥ 815¥ 1903¥ 2718¥ 6795¥ 27180
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
WB圖
通過ISO 9001、ISO 13485質量體系認證
特異性
該抗體是針對uPAR的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別uPAR。
用法
免疫印跡：0.2-2μg/mL;1:250-2500
免疫組織化學：5-20μg/mL;1:25-100
免疫細胞化學：5-20μg/mL;1:25-100
最佳稀釋倍數(shù)最終由用戶決定。
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質期內，在適當?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA141Mu01 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA141Mu01 | 尿激酶型纖溶酶原激活因子受體(uPAR)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA141Mu02 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA141Mu01 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA141Mu02 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA141Mu71 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| LAA141Mu81 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| SEA141Mu | 尿激酶型纖溶酶原激活因子受體(uPAR)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA141Mu | 尿激酶型纖溶酶原激活因子受體(uPAR)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| International Journal of Cancer | Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice[Wiley: source] |
| Biomark Insights | Decreased Epidermal Growth Factor (EGF) Associated with HMGB1 and Increased Hyperactivity in Children with Autism[PubMed: PMC3623607] |
| Biomarker insights | Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD)[PubMed: PMC3762604] |
| Am J Emerg Med | Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis[PubMed: 26615223] |
| Archives of Clinical Infectious Diseases | Evaluation of Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Sepsis[Archcid: 26346] |
| The American Journal of Emergency Medicine | Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic Cavia (Guinea pig )idance of sepsis[science:S0735675715009559] |
| Journal of Clinical and Experimental Hepatology | Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD)?…[10.1016:j.jceh.2018.02.001] |
| Turkish journal of trauma & emergency surgery | The diagnostic value of serum urokinase-type plasminogen activator receptor in acute appendicitis[Pubmed: 31475329] |
| CELL TRANSPLANTATION | Predictive Value of Degranulating Factors of Neutrophils in Massive Cerebral Infarction[33787356] |